Abstract
Rivaroxaban after total knee arthroplasty (TKA) is used to prevent postoperative venous thromboembolism (VTE); however, despite thromboprophylaxis, some patients still develop postoperative VTE. To determine whether tourniquet time, time to initiate rivaroxaban (TTIRIV), or Body Mass Index (BMI) was associated with postoperative VTE. A retrospective case-control study was conducted. Those patients that developed VTE despite prophylaxis (cases) were compared to controls (no VTE). A univariate analysis was conducted (p < 0.05 statistically significant). Seven VTE cases were identified from 234 TKA-patients. Patients with and without VTE had BMI of 40.1 ± 9.1 and 32.8 ± 7.5, respectively (p = 0.064). TTIRIV in VTE and control group was 28.2 ± 4.7 hours and 26.4 ± 4.2 hours, respectively (p = 0.39). Mean tourniquet time in VTE and control group was 65.0 ± 8.7 minutes and 49 ± 8.8 minutes, respectively (p = 0.0007). Statistically significant differences in tourniquet times were noted between VTE and non-VTE group but not for TTIRIV and BMI. Prolonged tourniquet use could pose a potential risk factor for postoperative VTE. Thromboprophylaxis management may need to be adjusted, based on patient-specific factors that could include increasing doses of oral anticoagulants and/or mechanical prophylaxis. However, further large-scale studies are required to establish pathophysiology.
Keywords:
body mass index; orthopedic surgery; rivaroxaban thromboprophylaxis; tourniquet; venous thromboembolism.
MeSH terms
-
Aged
-
Arthroplasty, Replacement, Knee / adverse effects*
-
Arthroplasty, Replacement, Knee / methods
-
Case-Control Studies
-
Factor Xa Inhibitors / pharmacology
-
Factor Xa Inhibitors / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Retrospective Studies
-
Risk Factors
-
Rivaroxaban / pharmacology
-
Rivaroxaban / therapeutic use*
-
Venous Thromboembolism / drug therapy*
Substances
-
Factor Xa Inhibitors
-
Rivaroxaban